Welcome back to Health Unlocked, where we dive deep into the real-world challenges and breakthroughs in health innovation. In today’s episode, we’re joined once again by Jasen Petersen, who tackles some of the unanswered questions from previous conversations, this time pulling back the curtain on what “terrain support” actually means for patients and practitioners. We explore how the regulatory landscape shapes which claims can be made about cutting-edge products like Ion Gel, and why certain benefits remain unsaid even when the evidence is compelling. Jasen takes us through the complex process of classifying medical devices, what it means for safety and accessibility, and the strategic thinking behind spinning off development companies to advance multiple health solutions without sacrificing focus or effectiveness. Plus, we get a glimpse into how the future of funding and innovation might look, where collaboration thrives and skepticism, even from the scientific community, drives progress. Stick around for a candid, thoughtful conversation on the intersections of science, regulation, and building something truly new in health care.
Timestamps:
00:00 Discovering wound healing insights
04:24 Class 1 medical device safety
09:21 Goal of developing Class 1 device
13:15 Promoting a new wound healing gel
15:19 Prioritizing safety and funding strategies
19:24 Observing wound healing process
22:47 Focusing on wound healing startups
27:03 Valuing different components of IP
28:41 Collaborative company operations strategy
31:39 Drug development and investor milestones
36:38 Nonprofit funding strategy teaser
40:52 Community event with parade and helicopter
42:52 Large turnout for 250th Fun Run
Insights from Health Unlocked: The Power of Salutogenesis with Jasen Petersen – Understanding Regulatory Claims, Innovation, and Funding Models
Are you intrigued by the intersection of medical innovation, regulatory hurdles, and funding strategies in healthcare? The latest episode of Health Unlocked: The Power of Salutogenesis with Jasen Petersen offers a deep dive into these topics, demystifying terms like “terrain support,” explaining FDA device classes, and unpacking the business models that drive breakthrough products to the market. Here’s a summary of key insights from the episode, perfect for healthcare entrepreneurs, practitioners, and anyone interested in cutting-edge health solutions.
What Does "Terrain Support" Really Mean?
Throughout the episode, Jasen addresses questions left open from previous discussions, focusing first on the highly marketed term "terrain support." If you’ve seen these claims on medical products, you might wonder what practitioners are truly allowed to say versus what the product actually does.
According to Jasen, "terrain support" is a vague concept, often used in cosmetics to bypass stringent medical claims. The FDA and regulatory agencies are still grappling with how to classify such terms, primarily because they lack a deep understanding of micro-immune dynamics. For products like Ion Gel, while it is labeled as antimicrobial and antioxidant, these designations fall short of representing its full spectrum of benefits.
The limitation is not scientific—it’s regulatory. Doctors understand that these products work upstream to address chronic disease likelihood, but regulations restrict what can be said publicly. This bottleneck shapes the language used around products on the market, inevitably confining transformative innovations to claims that appear softer or less impactful than the underlying science supports.
FDA Device Classes and Their Implications
A significant segment of the podcast is devoted to the differences between Class 1 and Class 2 medical devices and what these distinctions mean for practitioners and patients. Jasen explains that gaining Class 1 classification is mostly about proving safety. Even though the product may provide potent antimicrobial benefits, for a Class 1 device, you cannot legally claim that it treats specific conditions such as chronic wounds. You can only position it as preventative or supportive.
This regulatory approach means companies often reduce the concentration in Class 1 products so that they align with the lower-risk claims (e.g., similar to antimicrobial honey used in wound care). This doesn't make the product less beneficial, but it limits the claims manufacturers can make, keeping them within the boundaries set by the FDA.
Innovating Within Regulatory Boundaries
One fascinating takeaway is how companies like the one led by Jasen use regulatory stepping stones to bring innovations to market. Starting at Class 1 proves safety, builds trust, and demonstrates compliance. Later, companies can pursue Class 2 and eventually drug status as more data builds and funding allows.
Innovation here does not only refer to science. It also involves creating organizational structures that allow multiple products to be developed for varying indications without diluting focus or overwhelming management. For example, the IP is held by a nonprofit foundation, which then licenses targeted bundles to focused spinout companies for each use case (wound healing, psoriasis, etc.).
A New Model for Funding and Growth
The funding strategy discussed by Jasen is truly innovative. The nonprofit gathers the intellectual property, creates tailored spinouts with focused teams, and supports them through initial development and funding. As each company is proven in one indication, it becomes easier to attract funding and prove efficacy in others.
Practitioners or business owners interested in these products can trial the cosmetic versions without needing to make medical claims. If a practitioner or investor wants to prove a product for a particular indication, Jasen recommends direct engagement: test the product, gather data, and decide if it’s worth deeper collaboration or investment.
Community Empowerment and Collaborative Growth
At its core, this model empowers practitioners, entrepreneurs, and communities. Collaboration and decentralized science keep decision-making open, encourage data sharing, and ensure that innovations don't stall if one spinout is bought or closed. This approach enables maximal impact without stifling future growth or cross-pollination between indications.
In summary, Health Unlocked’s latest episode is a must-listen if you care about genuine innovation in health and wellness. It reveals both the constraints and creative pathways driving new medical products from the lab all the way to patient care. Make sure to tune in for the full insights directly from Jasen, and stay connected for future episodes exploring funding strategies, regulatory navigation, and what’s next in salutogenic healthcare solutions.
“Disclaimer: Informational only. Not medical advice. Consult your doctor for guidance.”
Show Website - https://powerofsalutogenesis.com/
Ionic Alliance Foundation Website - https://iaf.care/
Jasen Petersen's LinkedIn - https://www.linkedin.com/in/jasenepetersen/
TopHealth Media Website - https://tophealth.care/